Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Debate over compounding bill centers on supplier verification, patient safety and access
Summary
HB 2,613 would require tighter quality-assurance measures for compounded drugs; drugmakers and patient‑safety groups urged safeguards targeting high‑volume, mass‑marketed compounded GLP‑1 products, while pharmacists, hospitals and community clinics warned the bill as written would overreach, raise costs, delay care and risk limiting essential patient‑specific compounding.
Lawmakers, industry and healthcare providers offered sharply contrasting views Friday during a public hearing on House Bill 2,613, which would tighten quality‑assurance and supply‑chain verification requirements for compounded drugs.
Emily Poole, committee staff, told the House Health Care and Wellness Committee the bill would prohibit sale, transfer or distribution of a compounded drug unless the compounder uses bulk drug substances that meet national standards or appear on an FDA list, maintains certificates of analysis, performs quality control testing, and can show the manufacturer of the bulk substance is FDA‑registered and inspected within the last two years. The bill also would require two years of record retention and authorizes the pharmacy…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
